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ABSTRACT Clostridium difficile colonizes the gastrointestinal (GI) tract, resulting in
either asymptomatic carriage or a spectrum of diarrheal illness. If clinical suspicion
for C. difficile is low, stool samples are often submitted for analysis by multiplex mo-
lecular assays capable of detecting multiple GI pathogens, and some institutions do
not report this organism due to concerns for high false-positive rates. Since clinical
disease correlates with organism burden and molecular assays yield quantitative
data, we hypothesized that numerical cutoffs could be utilized to improve the speci-
ficity of the Luminex xTAG GI pathogen panel (GPP) for C. difficile infection. Analysis
of cotested liquid stool samples (n  1,105) identified a GPP median fluorescence
intensity (MFI) value cutoff of 1,200 to be predictive of two-step algorithm (2-SA;
96.4% concordance) and toxin enzyme immunoassay (EIA) positivity. Application of
this cutoff to a second cotested data set (n  1,428) yielded 96.5% concordance. To
determine test performance characteristics, concordant results were deemed positive
or negative, and discordant results were adjudicated via chart review. Test perfor-
mance characteristics for the MFI cutoff of 150 (standard), MFI cutoff of 1,200,
and 2-SA were as follows (respectively): concordance, 95, 96, and 97%; sensitivity, 93,
78, and 90%; specificity, 95, 98, and 98%; positive predictive value, 67, 82, and 81%;,
and negative predictive value, 99, 98, and 99%. To capture the high sensitivity for
organism detection (MFI of 150) and high specificity for active infection (MFI of
1,200), we developed and applied a reporting algorithm to interpret GPP data
from patients (n  563) with clinician orders only for syndromic panel testing, thus
enabling accurate reporting of C. difficile for 95% of samples (514 negative and 5
true positives) irrespective of initial clinical suspicion and without the need for addi-
tional testing.
KEYWORDS two-step algorithm, Clostridium difficile, community-associated
infections, quantitative thresholds, syndromic panels
Clostridium difficile causes a spectrum of gastrointestinal (GI) illnesses ranging frommild diarrhea to toxic megacolon and death (1). Asymptomatic carriage has been
identified in up to 15% of healthy adults, with increased colonization rates in individ-
uals with repeated exposures to dysbiotic agents (e.g., antibiotics, chemotherapy,
immune suppressants, etc.) and in up to 50% of elderly patients residing in long-term
care facilities (2). A review of the primary causes of nosocomial diarrhea highlight20%
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of cases as attributable to C. difficile infection, with the majority due to medications, 
enteral feeding, or underlying illness (3). This combination renders nucleic acid ampli-
fication tests (NAATs) highly susceptible to false positives (4), the consequences of 
which include subjecting patients to the side effects of unnecessary antibiotics, pro-
motion of multidrug-resistant enteric microbiota (including vancomycin-resistant en-
terococci), further propagation of microbial dysbiosis, and failure to identify the un-
derlying cause of diarrheal illness (3). In contrast, protein toxins are acid, heat, and 
enzymatically labile (5–7) and susceptible to neutralization by host-derived (8–10) and 
therapeutic antibodies (11), contributing in part to the reduced sensitivity of toxin 
enzyme immunoassays (EIAs) to milder forms of disease harboring low organism 
burden and toxin production (12). The consequences of false-negative results can be 
severe, including increased patient morbidity and mortality and loss of clinician con-
fidence in C. difficile testing results.
These innate testing vulnerabilities are well known and in the absence of definitive 
expert consensus guidelines have sparked three major approaches to directed C. 
difficile diagnostic testing (1, 5). A March 2016 Clinmicronet survey (a global listserv of 
doctoral clinical microbiologists) showed the following breakdown in diagnostic testing 
practices among respondents (n  70): (i) NAAT-only approach (78%), (ii) an algorithm 
utilizing glutamate dehydrogenase (GDH) as a screen followed by toxin EIA and 
adjudication of toxin-negative cases with PCR (13%); two-step algorithm [2-SA], and (iii) 
an algorithm utilizing GDH or NAATs as a screen and confirmation of toxin-positive 
cases with a toxin EIA (9%) (5). Regardless of local diagnostic testing practices, typical 
case presentations such as diarrheal illness in an antibiotic-exposed elderly individual 
evoke high suspicion for C. difficile, triggering clinicians to order directed testing. In 
contrast, patients without obvious antibiotic use or recent hospital exposure in the 
preceding 12 weeks (i.e., community onset) raise a broad differential with low suspicion 
for C. difficile, prompting orders for testing methodologies (stool culture, ova parasite, 
and syndromic panels) that do not detect this organism (12, 13). Some laboratories that 
perform multiplex assays targeting C. difficile choose to hide results for this organism 
out of concern for high false-positive rates. With an estimated incidence of community-
associated C. difficile infections (CA-CDI) ranging from 1.5% to 15% of total CDI (14–17), 
it is troubling to note that up to 60% do not elicit an order for directed testing (18). 
Although most of these infections will be self-limited, a subset of patients would likely 
benefit from treatment enabling faster symptom resolution and prevention of serious 
sequelae (19). Furthermore, knowledge of C. difficile involvement in their diarrheal 
illness would relieve patient anxiety, trigger precautions around susceptible close 
contacts, and increase clinical suspicion should symptom onset recur.
Recent efforts to improve NAAT specificity have honed in on quantitative real-time 
PCR cycle threshold (CT) values reflective of organism burdens that predict toxin EIA 
positivity (20–24). Although reported out qualitatively, the Luminex xTAG GI pathogen 
panel (GPP; targets 14 GI pathogens including C. difficile) also yields quantitative data 
measured in median fluorescence intensity (MFI) units (13, 25, 26). In this study, we 
show that an algorithmic approach utilizing high and low quantitative MFI cutoffs 
improves the specificity of the Luminex GPP for active infection without compromising 
the assay’s high sensitivity for organism detection. This approach enables accurate 
detection and reporting of C. difficile from this multiplex assay irrespective of clinical 
suspicion, enabling identification of a subset of previously undiagnosed patients.
MATERIALS AND METHODS
Processing and analysis of patient samples utilizing the 2-SA and the Luminex xTAG GPP. Stool 
samples with clinician orders for C. difficile testing sent to the Clinical Microbiology and Immunology 
Laboratories at the University of North Carolina (UNC) Health Care Hospital in Chapel Hill, NC, were 
assayed utilizing the 2-SA (1). At our institution, the 2-SA begins with the Alere C. diff Quik Check 
Complete EIA (Waltham, MA) (used per the manufacturer’s instructions), which simultaneously tests for 
the presence of GDH (a sensitive screen targeting C. difficile with cross-reactivity to other Clostridium 
species) and toxins A and B. All GDH-negative (GDH) samples are reported out as negative, GDH-
positive (GDH)/toxin-positive samples are reported out as positive, and GDH/toxin-negative samples 
are reflexed to the Cepheid Xpert C. difficile PCR assay targeting the toxin B gene (tcdB) (Sunnyvale, CA)
(used per the manufacturer’s instructions) and reported based on the PCR result. The 2-SA is restricted 
to specimens that take the shape of the container and is not performed on patients that are 1 year old, 
have documented laxative use (48 h prior), or have had a negative C. difficile test within the previous 
7 days or a positive one in the past 14 days.
Our institution additionally offers the Luminex xTAG GI pathogen panel (GPP) multiplex PCR assay 
(Austin, TX), which is capable of simultaneously detecting 14 GI pathogens (13). Unlike 2-SA testing, there 
is no age restriction for ordering the GPP. The test is performed on stool specimens from outpatients and 
inpatients (hospitalized for 3 days) that conform to the shape of the container. The pathogens reported 
out from this assay at our institution include Campylobacter, Salmonella, Shigella, Escherichia coli O157, 
Shiga toxin-encoding E. coli (STEC), Giardia, Cryptosporidium, rotavirus, and norovirus. During the time 
frame of the current study, C. difficile GPP data were not reported out of concern for high false-positive 
rates. The procedure is performed as per the manufacturer’s instructions, with the exception that raw 
median fluorescence intensity (MFI) values were analyzed for this study. The assay involves PCR 
amplification and hybridization of biotinylated amplicons to cDNA probes bound to beads with unique 
fluorescence spectral patterns and to phycoerythrin (PE)-labeled streptavidin. The beads are then passed 
through a flow cytometer, identified via unique UV light fluorescence patterns, and analyzed for the 
presence and quantity of bound amplicons (MFI values). The identified bead is matched to a particular 
organism, and the associated MFI value is compared to a predetermined threshold to determine the 
presence or absence of the infectious agent. For C. difficile, the standard positive MFI threshold is 150 
for genes encoding either toxin A or toxin B. Although typically concordant, data from averaged MFI 
values for toxins A and B were evaluated in the current study to improve assay specificity and mitigate 
false positives caused by high MFI values associated with one toxin alone. Given the low initial clinical 
suspicion for C. difficile in samples submitted for syndromic panel testing, we favor the improved 
specificity of data interpretation with averaged MFI values.
At our institution, GPP analysis of stool samples is performed in singlicate, and the reproducibility of 
toxin A and toxin B MFI values in this retrospective data set could not be assessed. Based on GPP 
precision data submitted to the FDA and precision studies performed in our laboratory for targets other 
than C. difficile (not reported from the GPP for clinical use at the time of this study), we would expect 
some quantitative but not qualitative variation in MFI values on repeat testing.
Identification of a GPP MFI threshold predictive of 2-SA and toxin EIA positivity. At our 
institution, clinicians ordering the 2-SA alone have a relatively high suspicion for C. difficile involvement. 
Clinicians with low suspicion order the GPP assay alone, and those who are unsure cast the broadest 
diagnostic net possible and order both assays, creating a data set to evaluate test performance 
characteristics and optimize the GPP assay. Tables 1 and 2 list the individual test results, demographic 
information, and inpatient versus outpatient status for data sets 1 to 3. A retrospective data review was 
performed using the UNC Health Care laboratory information system to identify patients with stool 
samples tested by the GPP and 2-SA from July 2013 to June 2014. These cotested samples (n  1,105)
(Table 2, data set 1) were analyzed by both assays utilizing either the same specimen or a second 
specimen collected within 24 h. The correlation of the 2-SA and its individual components (GDH EIA, 
toxin EIA, and reflex Xpert PCR) with GPP MFI values was independently analyzed. Receiver operator 
curves (ROC) were performed on data obtained from data set 1 utilizing GraphPad Prism to identify a GPP 
MFI value predictive of 2-SA and toxin EIA results. To examine the robustness and applicability of this MFI 
cutoff over time and between multiple reagent lots, equipment updates, and variations in testing 
personnel, we performed similar ROC analysis of data (Table 2, data set 2) obtained from a second group 
of patients (n  1,432) with cotested stool samples analyzed between July 2014 and June 2015.
Determination of test performance characteristics. Table 3 highlights the approach taken to 
render a final interpretation for the presence of active infection for each cotested sample in data set 1. 
NAATs have high analytical sensitivity for the detection of an organism; therefore, samples negative for 
both the GPP (NAAT) and 2-SA (n  917; GPP and 2-SA, respectively) were deemed negative for active 
infection. Detection of preformed toxin in stool correlates with clinical disease and patient outcome (27). 
Toxin EIAs target preformed toxin, and most exhibit very high specificity for active infection (12). The 
Alere QuikChek complete assay utilized in the current study exhibits 99% specificity, with cell 
cytotoxicity neutralization as the gold standard (12, 28). Although a subset of patients with toxin-positive 
EIA results may be asymptomatic (in vivo antibody mediated neutralization of toxin), detection of the 
etiologic agent of disease denotes metabolically active toxin-producing C. difficile, and patients in the 
toxin-positive EIA cohort (n  56) were considered to have active infection without additional chart 
review. Patients with discordant test results including GPP/PCR-positive (PCR) (n  7) and GPP-positive 
(GPP)/2-SA (n  55) were adjudicated by chart review (described further below). GPP/PCR cases 
(n  70) were also adjudicated via chart review, given the ability of NAATs to detect colonization in the 
absence of active infection.
Adjudication of discordant results via chart review. It is not possible to perform a thorough chart 
review without reading the results of C. difficile laboratory tests embedded within the patient notes and 
lab results contained in the medical record. Therefore, all clinical data were extracted from the medical 
record by two authors of the current study (S. M. Leal, Jr., and K. J. Levinson). The extracted clinical 
information was deidentified and removed of all information pertaining to C. difficile-specific test results 
for the encounter in question. The clinical vignette and associated lab parameters were independently 
analyzed by three infectious disease clinicians (B. Lehman, T. M. John, and M. B. Rios) blinded to the 
results of C. difficile laboratory tests utilizing the criteria outlined in Table 4 to render a clinical opinion 
(yes or no) on whether the patient was actively infected by C. difficile. The majority opinion (2/3) 
determined the final interpretation for that case. Defined criteria outlined in Table 5 were then utilized
TABLE 1 Patient characteristics by data set
Data set and patient characteristica No. (%) of patients
Data set 1 (n  1,105)
Age (yr)
18 169 (15.5)
18–64 688 (63.0)
65 236 (21.5)
Female 610 (55.9)b
Male 483 (44.1)
Inpatient 630 (57)
Outpatient 475 (43)
Data set 2 (n  1,428)
Age (yr)
18 188 (13.2)
18–64 906 (63.4)
65 334 (23.4)
Female 738 (51.7)
Male 690 (48.3)
Inpatient 650 (45.5)
Outpatient 778 (54.5)
Data set 3 (n  563)
Age (yr)
18 169 (30.0)
18–64 296 (52.6)
65 98 (17.4)
Female 310 (55.0)
Male 253 (45.0)
Inpatient 205 (36.4)
Outpatient 358 (63.6)
aData sets were collected as follows: data set 1, cotested samples analyzed from July 2013 to June 2014; 
data set 2, cotested samples analyzed from July 2014 to June 2015; data set 3, GPP samples without 
concomitant 2-SA testing analyzed from July 2013 to June 2014.
bThe medical records of 12 patients in this data set were inaccessible, and therefore the age and sex of 
these individuals could not be determined.
to categorize the severity of illness for each positive case. Disease severity stratification was used to 
identify actively infected patients in this cohort that would have benefited most from laboratory 
diagnosis. This study was not powered for definitive assessment of MFI correlation with disease severity. 
Likewise, although a subset of patients were more likely to be asymptomatically colonized by C. difficile 
(including immunocompromised individuals), this study was not powered to identify MFI thresholds 
uniquely predictive of active infection in these cohorts.
Table 4 lists the set of criteria that must be met to categorize an active infection. The presence of 3 
documented liquid stools per 24 h is required and was determined by reading clinician notes and nursing 
documentation in the medical record at the time the test was performed. In addition, the keyword search 
function was used in Epic to scan clinic notes and lab results within the appropriate time frame using 
keywords such as “bowel movements,” “BM,” “diarrhea,” and “stool.” Similarly, documented use of 
dysbiotic agents (antibiotics, chemotherapy, or immunosuppressants) within the past 2 months or a 
documented history of a prior C. difficile infection (6 months prior) or susceptible patient population 
(defined by inflammatory bowel disease [IBD], graft-versus-host disease [GVHD], cystic fibrosis [CF], or 
age 65 years) was determined by reading medical notes, medication history, problem lists, and 
searching with the keywords “antibiotics,” “infection,” “immunosuppressant,” “steroid,” “tacrolimus,” 
“biologics,” “recurrent,” and “difficile.” No laxative use within 48 h of symptom onset was determined by 
reading clinician notes and searching for documented usage up to 48 prior to the test date with the 
keywords “laxative,” “MiraLAX,” “Dulcolax,” “senna,” and “polyethylene glycol.”
The additional criteria listed in Table 4 are not required to categorize active infection but, rather, aid 
in the interpretation of specific clinical scenarios. Improvement on antibiotics with activity against C. 
difficile favors active infection, and this information was determined by reading initial clinician notes, 
searching for the prescription of relevant medications (flagyl, metronidazole, vancomycin, and fecal 
transplant), and reading follow-up notes to determine treatment efficacy. The absence of sick contacts 
with individuals with similar symptoms argues against readily transmissible GI pathogens and was 
determined by reading clinic notes and searching for “sick contacts.” The absence of another GI 
pathogen identified by laboratory assays also argues against alternative infections, and this information 
was obtained during the initial download of data sets 1 to 3. To rule out viral gastroenteritis, provider 
notes were read to identify cases in which emesis began prior to and exceeded diarrheal illness. Irritable 
bowel syndrome (IBS) was ruled out by searching for the terms “irritable bowel syndrome,” “IBS,” and 
“diarrhea” to detect any prior diagnosis of this condition and to identify patients with a long-standing
TABLE 2 Test results by data set
Data seta
Test resultb
No. of samplesGPPc 2-SA (component)
Data set 1 (n  1,105) Neg Neg (GDH) 854
Neg Neg (PCR) 63
Neg Pos (PCR) 7
Neg Pos (Toxin)d 2
Pos Neg (GDH) 54
Pos Neg (PCR) 1
Pos Pos (PCR) 70
Pos Pos (Toxin) 54
Data set 2 (n  1, 428) Neg Neg (GDH) 1,138
Neg Neg (PCR) 62
Neg Pos (PCR) 7
Neg Pos (Toxin) 3
Pos Neg (GDH) 75
Pos Neg (PCR) 3
Pos Pos (PCR) 80
Pos Pos (Toxin) 60
Data set 3 (n  563) Neg NDe 514
Neg ND 49
aData sets were collected as follows: data set 1, cotested samples analyzed from July 2013 to June 2014; 
data set 2, cotested samples analyzed from July 2014 to June 2015; data set 3, GPP samples without 
concomitant 2-SA testing analyzed from July 2013 to June 2014.
bPos, positive; Neg, negative.
cPositive and negative results with the Luminex GPP assay in these datasets were determined based on the 
standard MFI threshold of 150.
dPositive for toxin by EIA.
eND, not done.
history of recurrent mild diarrheal illness that resolved without C. difficile-specific treatment. Comparison 
of the current illness to prior diarrheal episodes was used to detect any change above baseline levels 
indicating active infection. Inflammatory bowel disease (IBD) flares were ruled out based on the 
frequency (above baseline level favors infection), consistency (more watery/malodorous than bloody 
favors infection), and symptom resolution upon antibiotic treatment (favors infection) and not immu-
nosuppressant therapy alone (favors IBD).
Table 5 lists the criteria to categorize an active infection as either mild, moderate, severe, or 
fulminant. If diarrheal illness was the only active pathology (often the case for outpatients), then all 
systemic symptoms were attributed to it. If active comorbidities were present but symptoms initiated or 
worsened with the onset of diarrheal illness, they were attributed to the GI illness; otherwise criteria were 
not attributed to C. difficile infection. Data on the number of bowel movements (BMs) per 24 h were 
extracted from the medical record as described above. Mild cases exhibited 3 BM per 24 h, whereas 
moderate cases additionally exhibited systemic symptoms: temperature of 38°C or elevated creatinine 
(increased but 1.5 baseline) that initiated or worsened at the time of diarrheal illness. The presence 
and timing of systemic symptoms were determined based on clinician notes and searching Epic with 
the keywords “fever,” “vital signs,” and “creatinine” and reading through documents/lab results in the 
corresponding time frame. Severe cases additionally exhibited either radiologic, colonoscopic, or path-
ological evidence of pseudomembranous colitis or at least three of the listed criteria: elevated creatinine 
(1.5 baseline), elevated lactate (increased but 5 mmol/liter), serum albumin (increased but 2.5 
mg/dl), peripheral white blood cell (WBC) count of 15,000/mm3, an intensive care unit (ICU) stay 
attributable to the diarrheal illness, or age of 65 years. Patient age and peak lab results at the time of 
diarrheal illness were readily extracted from the medical record. The presence or absence of an ICU stay 
associated with the diarrheal illness and pseudomembranous colitis (PMC) was determined by reading 
provider notes and searching the key terms (“ICU,” “intensive care,” “pseudomembranous colitis,” 
“colitis,” and “PMC”). Fulminant infections were characterized by the presence of either toxic megacolon, 
death within 30 days due to diarrheal illness, or the presence of elevated serum lactate (5 mmol/liter) 
and a leukemoid reaction (50/mm3). Provider notes and key term searches (“toxic megacolon” and 
“death”) were used to detect radiologic, colonoscopic, or pathological evidence of toxic megacolon and 
death.
Application of an MFI threshold-based reporting algorithm to detect C. difficile infection. We 
developed an algorithm (see Fig. 3) to report C. difficile results from the Luminex GPP based on high and 
low MFI threshold cutoffs and applied this reporting algorithm to a fresh data set (July 2013 to June 2014; 
n  563) (Table 2) of patient samples analyzed by the GPP without 2-SA testing (indicative of low initial 
clinical suspicion). Next, we determined the percentage of samples that could be directly reported to 
treating clinicians as either positive or negative for the toxin gene based on the low MFI threshold (high 
sensitivity for organism), with a comment indicating organism burden suggestive of (or indeterminate
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for) active infection based on the high MFI threshold (high specificity for active infection). Chart reviews
were performed on a subset of patients in data set 3 to determine the number of active infections in
patients with MFI values of 1,200, and 15/21 medical records were available for review.
Statistics. GraphPad Prism (San Diego, CA) was utilized to assess the statistical significance of GPP
MFI values corresponding to specific experimental variables. Nonparametric two-tailed t tests (Mann-
Whitney test) were used to analyze the statistical significance between two data groups. Nonparametric
one-way analysis of variance (ANOVA; Kruskal-Wallis test) with Dunn’s posttest analysis was used to
analyze the significance between 2 experimental variables. Test performance characteristics (concor-
dance, sensitivity, specificity, positive predictive value [PPV], and negative predictive value [NPV]) were
calculated via standard methods. The Clopper-Pearson method was used to calculate 95% confidence
intervals for each test performance characteristic. The statistical significance of test performance char-
acteristics was determined using McNemar’s test, and all P values of 0.05 were considered statistically
significant.
Study approval. This study was approved by the Institutional Review Board at the University of
North Carolina at Chapel Hill (Chapel Hill, NC).
RESULTS
Correlation of GPP MFI thresholds with 2-SA and toxin EIA positivity. To test the
hypothesis that GPP MFI thresholds could be utilized to predict 2-SA and toxin EIA
positivity, we analyzed 1,105 cotested samples (data set 1) with the individual test
results, demographic information, and inpatient versus outpatient status shown in
TABLE 4 Screening criteria to identify active C. difficile infection by chart reviewa
Active infection screening criteria
by type Description
Essential criteria
Symptoms 3 Documented liquid stools per 24 h
Exposure Documented use of dysbiotic agents (antibiotics, chemotherapy, or immunosuppressants 2 mo prior) or
documented history of a prior C. difficile infection (6 mo prior) or susceptible patient population
(positive for IBD, GVHD, CF, or age of 65)
Laxative use No laxative use within 48 h of symptom onset
Additional criteria
Treatment response Improvement on antibiotics with activity against C. difficile
Initial clinical suspicion Extent of treating clinician’s initial suspicion for active infection prior to receiving laboratory test results
Exclusion of alternative diagnoses No sick contacts with individuals with similar symptoms; no other GI pathogen identified by laboratory
assays; not VGE (diarrhea illness with emesis that begins before nausea/vomiting); not IBS (persistent
disease until treatment; does not wax and wane); not IBD (diarrhea frequency above baseline;
consistency is more watery/malodorous than bloody; symptom resolution upon antibiotic exposure,
with or without immunosuppression)b
aChildren 3 years old are not included in this study given high rates of C. difficile carriage.
bSick contacts with similar symptoms significantly decreases the likelihood of C. difficile infection; symptoms that wax and wane without treatment is suggestive of
irritable bowel syndrome (IBS). VGE, viral gastroenteritis; IBD, inflammatory bowel disease.
TABLE 5 Criteria to determine the severity of active C. difficile infection
Symptom(s)
Description or importance by degree of infectiona
Mild Moderate Severe Fulminant
No. of bowel movements/24 h 3 3 3 Not predictive
Systemic symptoms
Temp (°C) 38 38 38
Elevated creatinine 1.5 Baseline level 1.5 Baseline level 1.5 Baseline level
Serum lactate Elevated but 5 mmol/liter 5 mmol/liter
Serum albumin 2.5 mg/dl 2.5 mg/dl
Peripheral WBC count 15,000/mm3 Leukemoid (50/mm3)
Intensive care unit stay Present Present
Patient age (yr) 65 65
Pseudomembranous colitis Defines category Present
Toxic megacolon (diam, 6 cm) Defines category
Death within 30 days due to C. difficile Defines category
aMild, 3 BM/24 h with no systemic symptoms; moderate, 3 BM/24 h plus 1 systemic symptom originating or worsening after the onset of diarrheal illness;
severe, 3 BM/24 h plus pseudomembranous colitis or 3 of the listed criteria; fulminant, 3 BM/24 h or constipation plus either (i) toxic megacolon, (ii) death due
to C. difficile infection, or (iii) WBC of 50 and serum lactate 5.
FIG 1 Analysis of cotested samples identifies a GPP quantitative MFI threshold of 1,200 as predictive of 2-step algorithm and toxin EIA results. (A) GPP
averaged toxin A/B MFI values corresponding to 2-SA-negative and -positive cases. (B) Receiver-operator curve (ROC) analysis of GPP MFI values as a function
of 2-SA results. (C) GPP MFI values corresponding to the results of individual components in the 2-SA, including GDH antigen, reflex PCR, and toxin EIAs. (D)
ROC analysis of GPP MFI values as a function of toxin EIA results. Individual data points, the mean, and 95% confidence intervals indicated by the error bars
are shown for each experimental variable. Std, standard.
Tables 1 and 2. In this study, we sought to identify an MFI cutoff with high specificity 
and therefore averaged toxin A and B (A/B) MFI values to reduce false positives (toxin 
A, 1/1,105, or 0.1%; toxin B, 3/1,105, or 0.3%) caused by high MFI values associated with 
a single toxin.
Figure 1A shows a dot plot of averaged toxin A/B MFI values for 2-SA-negative and 
2-SA-positive cases. Individual data points, the mean, and 95% confidence intervals 
(indicated by the error bars) are highlighted for each experimental variable. 2-SA-
positive cases exhibited statistically significant increases (P  0.05) in MFI values 
compared with those of 2-SA-negative cases. Visual inspection of this graph shows an 
MFI cutoff of 1,200 (indicated by the dotted line) that accurately classified 962/973 
(99%) 2-SA-negative cases and 105/132 (80%) 2-SA-positive cases. Figure 1B shows a 
receiver operator curve (ROC) of GPP MFI values as a function of 2-SA results with a 
statistically significant (P  0.05) area under the curve (AUC). Data points representing 
the standard GPP MFI cutoff value of 150 and the more specific MFI cutoff value of 
1,200 are also indicated. Figure 1C shows a dot plot of averaged toxin A/B MFI values 
for individual components of the 2-SA (GDH antigen negative, reflex PCR negative-
[PCR], toxin-positive EIA, and reflex PCR). MFI values associated with toxin EIA and 
PCR cases show statistically significant differences (P  0.05) compared to values for
GDH and PCR cases. Application of an MFI cutoff of 1,200 (indicated by the dotted
line) accurately identified 897/908 (99%) of GDH cases, 64/64 (100%) of PCR cases,
53/56 (95%) of toxin-positive EIA cases, and 52/76 (68%) of PCR cases. Figure 1D
shows an ROC of MFI values as a function of toxin EIA results with a statistically
significant AUC (P  0.05) and highlighted data points representing the standard MFI
cutoff of 150 and the high-specificity MFI cutoff of 1,200. Although multiple cutoffs
were evaluated, the high specificity and acceptable sensitivity of an MFI cutoff of
1,200 were deemed optimal to predict 2-SA and toxin EIA positivity.
Correlation of the MFI cutoff of>1,200 to 2-SA and toxin positivity in a second
FIG 2 Application of the GPP MFI cutoff of 1,200 to a second cotested data set is predictive of 2-step algorithm and toxin EIA results. (A) GPP averaged toxin
A/B MFI values corresponding to 2-SA-negative and -positive cases. (B) ROC analysis of GPP MFI values as a function of 2-SA results. (C) GPP MFI values
corresponding to the results of individual components in the 2-SA. (D) ROC analysis of GPP MFI values as a function of toxin EIA results. Individual data points,
the mean, and 95% confidence intervals indicated by the error bars are shown for each experimental variable.
cotested data set. To examine the robustness and applicability of MFI thresholds over 
time and between multiple reagent lots, equipment updates, and variations in testing 
personnel, we applied this cutoff to a second group of patients (data set 2; n  1,428) 
with cotested stool samples. Figure 2A shows a dot plot of averaged toxin A/B MFI 
values for 2-SA-negative and 2-SA-positive cases. Differences in MFI values between 
both groups are statistically significant (P  0.05), and an MFI cutoff of 1,200 
accurately classified 1,258/1,278 (98%) of 2-SA-negative cases and 121/150 (81%) of 
2-SA-positive cases. Figure 2B shows an ROC of MFI values as a function of 2-SA results 
with a statistically significant AUC (P  0.05) and similar localization of MFI values.
Figure 2C shows a dot plot of averaged toxin A/B MFI values for individual components
of the 2-SA with statistically significant differences (P  0.05) in MFI values associated
with toxin-positive and PCR cases compared to GDH and PCR cases. Application of
an MFI cutoff of 1,200 accurately classified 1,193/1,213 (98%) GDH cases, 65/65
(100%) PCR cases, 56/63 (89%) toxin-positive cases, and 65/87 (75%) PCR cases.
Figure 2D shows an ROC of MFI values as a function of toxin EIA results with a
statistically significant AUC (P  0.05) and similar localization of MFI values. These data
indicate that the ability of an MFI cutoff of 1,200 to predict 2-SA and toxin EIA
positivity is robust over time and minimally susceptible to normal testing variations
(multiple reagent lots, equipment updates, variations in testing personnel, etc.) in the
clinical laboratory.
Adjudication of discordant samples via chart review. Table 3 outlines the
approach taken to render final interpretations for all cotested samples in data set 1
(n  1,105) and the results of chart review adjudication. GPP data used to render final
interpretations were obtained utilizing the standard MFI cutoff of 150 to achieve
optimal sensitivity and rule out the presence of a C. difficile strain encoding toxin genes
in the patient’s stool sample (no organism equates to no active infection). Chart reviews
were performed to adjudicate discordant test results and GPP/reflex PCR cotested
samples. During the chart review process, 6/132 individuals were excluded due to age
of 3 years (3 GPP/GDH and 3 GPP/PCR), and 7/132 patients (3 GPP/GDH and
4 GPP/PCR) were excluded due to inaccessible medical records. The extracted
clinical data from completed chart reviews (n  119) were interpreted by infectious
disease (ID) clinicians blinded to the results of laboratory tests, and the majority opinion
(2/3) determined the final interpretation for that case. Unanimous agreement between
all three clinicians was observed for 90/119 (76%) of cases. There were no specific
trends observed for the subset of patients (n  29) for which a unanimous agreement
was not reached. Of the 7 GPP/PCR cases, 4 were deemed negative and 3 were mild
positives by chart review. The following adjudication results were noted for the 54
GPP/GDH cases: 38 negative, 11 positive (3 mild, 7 moderate, and 1 fulminant), and
6 excluded (due to age or inaccessible medical record). The single GPP/PCR sample
was deemed a mild positive, and the 70 GPP/PCR cases exhibited the following
adjudication results: 20 negative, 42 positive (27 mild, 13 moderate, and 2 severe), and
7 excluded. These data (n  1,092) were used to determine the test performance
characteristics (concordance, sensitivity, specificity, negative predictive value, and pos-
itive predictive value) of each assay.
Test performance characteristics of the 2-SA and GPP MFI thresholds. Table 6
gives the test performance characteristics of the GPP interpreted with an MFI cutoff of
150 (standard), an MFI cutoff of 1,200, and the 2-SA (respectively): concordance,
94.5, 95.9, and 96.7%; sensitivity, 93.0, 77.9, and 89.4%; specificity, 94.7, 98.0, and 97.6%;
positive predictive value, 66.9, 81.5, and 80.8%; and negative predictive value, 99.2,
97.5, and 98.8%. McNemar’s test identified statistically significant differences (P  0.05)
in concordance between all three laboratory assays, decreased sensitivity of the MFI
TABLE 6 Sensitivity and specificity of the GPP versus the 2-step algorithma
Parameter
Test performance (%)b
GPP with:
2-SAMFI of >150 MFI of >1200
Concordance 94.5 (93.0–95.8) 95.9 (94.5–97.0) 96.7 (95.5–97.7)
Sensitivity 93.0 (86.5–96.9) 77.9 (69.1–85.1) 89.4 (82.2–94.4)
Specificity 94.7 (93.1–96.0) 98.0 (96.9–98.8) 97.6 (96.4–98.4)
PPV 66.9 (60.7–72.6) 81.5 (73.8–87.3) 80.8 (73.8–86.2)
NPV 99.2 (98.3–99.6) 97.5 (96.5–98.2) 98.8 (97.9–99.3)
aGPP interpretation with an MFI cutoff of 150 exhibits similar sensitivity to the 2-step algorithm and an
MFI cutoff of 1,200 exhibits similar specificity.
bBoldface indicates statistically significant differences in a comparison of results of all tests as determined by
utilizing McNemar’s test (P  0.05). Values in parentheses are 95% confidence intervals.
cutoff of 1,200, and decreased specificity of the MFI cutoff of 150 compared with
results of alternative assays. Table 7 shows that increasing the MFI threshold cutoff from
the standard of 150 to 1,200 eliminated 32 false positives at the expense of an
additional 17 false negatives and that an MFI cutoff of 150 produced 28 more false
positives and 4 fewer false negatives than the 2-SA. Table 7 also shows that raising the
MFI cutoff to 1,200 results in 4 fewer false positives at the expense of 13 additional
false negatives compared to results with the 2-SA.
Development and application of a GPP MFI threshold-based reporting algo-
rithm. Given the high sensitivity of the MFI cutoff of 150 and high specificity of the
MFI cutoff of 1,200, both thresholds were incorporated into a reporting algorithm
(Fig. 3) to report C. difficile results from the GPP assay with similar performance
characteristics as the 2-SA. In this algorithm, samples with MFI values of 150 are
TABLE 7 Comparison of GPP and two-step algorithm results and clinical results
Test type and result (n  1,092)
Clinical finding (no. of
samples)
Total no.
of resultsPositive Negative
GPP with MFI cutoff of 150
Positive 105 52 157
Negative 8 927 935
Total for group 113 979 1,092
GPP with MFI cutoff of 1,200
Positive 88 20 108
Negative 25 959 984
Total for group 113 979 1,092
Two-step algorithm
Positive 101 24 125
Negative 12 955 967
Total for group 113 979 1,092
FIG 3 Proposed algorithm to interpret GPP data enabling organism detection with high sensitivity (93%
if MFI 150) and active infection with high specificity (98% if MFI 1,200). An MFI cutoff of 1,200 yields 
96% concordance with the 2-step algorithm and 98% specificity for active infection (). An MFI cutoff 
of 150 yields a 99% negative predictive value for active infection (#). Samples destined for reflex testing 
() are positive for the organism (as detected by NAAT) and should be analyzed by an assay with high 
specificity for clinical disease (e.g., toxin EIA).
reported as negative for detection of the C. difficile toxin gene, with 93% sensitivity and
99% NPV. Samples with MFI values of 1,200 and no other pathogen detected are
reported as positive for detection of the C. difficile toxin gene and as having an
organism burden suggestive of active infection, with 98% specificity and 82% PPV.
Samples with MFI values in the intermediate range (150 but 1,200) or MFI values of
1,200 with concomitant detection of a second pathogen (possible false positive) are
reported out as positive for detection of the C. difficile toxin gene with additional
clinical scenario-dependent reflex testing. Samples destined for reflex testing are
known to harbor the organism (NAAT positive), and further adjudication with a
high-specificity assay (e.g., toxin EIA) is indicated to detect active infection. Positive or
negative adjudicated results should be reported as either suggestive of or indetermi-
nate for active infection, respectively.
In Fig. 4, we present data on reporting outcomes when this algorithm is applied to
563 samples (Table 2) without concomitant 2-SA testing (indicative of initial low clinical
suspicion). We show that 535/565 (95%) samples would have been immediately
reported to treating clinicians as either negative (514; 91%) or positive for C. difficile at
an organism burden suggestive of active infection (21; 4%) without the need for
additional testing. Of the 514 samples testing negative for C. difficile, 86 (17%) tested
positive for a GI pathogen. Chart reviews performed on patients with MFI values of
1,200 identified 5 patients with active infection (3 mild, 1 moderate, and 1 severe)
that did not receive C. difficile-specific testing. Samples with MFI values in the inter-
mediate range (23; 4%) or MFI values of1,200 with concomitant detection of a second
pathogen (5; 0.9%) would have been reported out as positive for C. difficile, alerting
clinicians to the possibility of active infection and availability of reflex toxin EIA testing
if warranted by the clinical scenario.
FIG 4 Algorithmic interpretation of GPP data enables accurate detection of infections from samples sent
only for syndromic panel testing, irrespective of clinical suspicion for C. difficile. Samples with an MFI of
1,200 (4%) or 150 (91%) are reported to treating clinicians as positive or negative, respectively,
without the need for additional testing (#). Samples with MFI values in the intermediate range (150 but
1,200; 4%) and samples positive for both C. difficile and a second pathogen (0.9%) are reported as
positive for the C. difficile toxin gene with optional reflex toxin EIA testing (). Of the 514 samples testing
negative for C. difficile, 86 (17%) tested positive for other pathogens (). Chart reviews identified 5/16
patients with undiagnosed active infection (3 mild, 1 moderate, and 1 severe) (*).
DISCUSSION
Classic presentations of C. difficile infection elicit high clinical suspicion and prompt 
providers to order laboratory tests specifically targeting this pathogen (1). However, 
presentations with symptom onset in the community and incomplete knowledge of 
associated risk factors result in up to 60% of infected outpatients not receiving tests 
capable of accurately detecting C. difficile (16, 18). This study aimed to fill this diagnostic 
void by identifying and applying quantitative cutoffs to the interpretation of data from 
the Luminex GI pathogen panel, enabling accurate detection of C. difficile infections 
from stool samples irrespective of clinical suspicion.
The algorithmic approach to reporting C. difficile from the GPP assay can be tailored
The need for reporting C. difficile from molecular syndromic panels is evident from 
recent reports on the epidemiology of CA-CDI. Hensgens et al. analyzed stool samples 
(n  12,714) submitted from outpatient settings in the Netherlands with either toxin 
EIAs or cell cytotoxicity neutralization assays (CCNA) and identified a CA-CDI rate of 
1.5% (n  191; the same rate as Salmonella gastroenteritis), with 60% (n  115) of these 
cases lacking clinician orders for C. difficile testing (18). Even if a careful history had 
captured all patients with recent antibiotic exposure or hospitalization, 39% (n  75) 
would have remained untested (18). Likewise, Wilcox et al. identified a CA-CDI rate of 
2.1% (by CCNA) in the United Kingdom, with 33% of patients lacking exposure to 
antibiotics (15). In the United States, stool samples submitted from emergency depart-
ments and outpatient clinics between 2002 and 2007 were prospectively analyzed by 
toxin EIAs, yielding a CA-CDI rate of 3.9%, with 37% lacking recent antibiotic exposure 
and 67% lacking hospitalization within the previous month (14). Since the introduction 
of stand-alone NAATs with increased sensitivity, epidemiologic data have indicated an 
increased rate of CA-CDI (17). Utilizing data obtained in 2011, the CDC estimated an 
annual incidence rate of 453,000 total cases of C. difficile in the United States, of which 
15.8% (n  71,574) exhibited symptom onset in the community and lacked docu-
mented inpatient health care exposure (16, 17). Given the high sensitivity of NAATs, the 
true incidence of CA-CDI is likely on the lower end of the spectrum of published figures, 
i.e., between 1.5 and 15.8% (15–17, 29). Although our study was not designed for 
epidemiologic purposes, we show a positivity rate consistent with the literature (4% to 
9%) in stool samples submitted for GPP analysis without directed testing for C. difficile.
The ability to report C. difficile from a syndromic panel is meant to supplement, not 
replace, directed-testing strategies. If clinical suspicion is high, targeted assays (2-SA 
and NAATs) should continue to be utilized as they are cheaper and faster, with 
comparable or better test performance characteristics and improved reimbursement 
rates (1, 12, 30, 31). If a clinician orders both directed testing and multiplex PCR analysis, 
C. difficile data could be reported out from both assays or reported solely from the 
directed-testing strategy. This decision would need to be made by individual lab 
directors as discordant results can lead to medico-legal/ethical dilemmas concerning 
whether to report a known positive test result. However, in the not infrequent situation 
in which low clinical suspicion triggers an order for multiplex PCR analysis but not 
directed testing, we propose that C. difficile data be reported from the Luminex GPP 
assay via the algorithm outlined in Fig. 3.
This algorithm takes advantage of a low MFI cutoff of 150 to accurately report 
detection of the organism with high analytic sensitivity (93%) and uses a high MFI 
cutoff of 1,200 to detect bacterial burden suggestive of active infection with high 
specificity (98%). The application of quantitative thresholds to interpret molecular data 
in the current study is similar to recent work utilizing PCR cycle threshold (CT) values to 
predict organism burden (21, 23), toxin EIA positivity (24), and patient outcome (20, 22). 
However, the current study is the first to apply quantitative cutoffs to a molecular 
syndromic panel enabling the accurate identification of C. difficile infection to the same 
extent as directed-testing strategies and the detection of patients with CA-CDI that 
would otherwise go undetected. Although most of these cases would resolve on their 
own (as with most diarrheal illness), a subset of patients with moderate to severe 
disease may have likely benefited from antimicrobial therapy with faster symptom 
resolution, decreased morbidity, prevention of serious sequelae, reduced risk of spread-
ing the disease, and increased clinical suspicion for C. difficile should symptom onset 
recur (19). In the inpatient setting, although the GPP assay has a longer turnaround 
time than directed-testing strategies, the ability to accurately identify patients with 
active infection who would otherwise not receive testing for C. difficile enables initiation 
of appropriate infection prevention measures, mitigating further propagation of the 
organism throughout the health care facility. Although our findings are specific to the 
Luminex GPP, it is possible that a similar approach could be utilized to report C. difficile 
from other multiplex PCR assays (13).
150. In this study, we observed 52 false positives using an MFI cutoff of 150 in
cotested samples in contrast to 20 and 24 for an MFI cutoff of 1,200 and the 2-SA,
respectively. If this approach were to be utilized, strict ordering restrictions (difficult to
enforce) that limit testing to patients with unexplained new-onset unformed stools
(3/24 h) who are not on laxatives are highly recommended to limit false positives, given
the relatively lower pretest probability of active infection in this cohort. Institutions
seeking to mitigate false positives can choose to report samples with MFI values of
1,200 as positive with specificity and PPV values similar to those of the 2-SA
(specificity, 98.0 versus 97.6%, respectively; PPV, 81.5 versus 80.8%, respectively).
to the philosophy of the individual institution. NAAT-only advocates utilizing strict 
preanalytic restrictions recommended by guidelines of the Infectious Diseases Society 
of America (IDSA) (32) may choose to take advantage of the high sensitivity of the GPP 
and report only detection of the C. difficile toxin gene for samples with MFI values of
Institutions that seek the benefits of high sensitivity for organism detection and high 
specificity for active infection can utilize the proposed reporting algorithm shown in 
Fig. 3. Samples with MFI values of 150 are reported as negative for the organism with 
a high NPV (99%), and those with MFI values of 1,200 are reported as positive for the 
organism, with a comment on bacterial burden suggestive of active infection (speci-
ficity, 98%). Samples in the intermediate category with an MFI of 150 but 1,200 
should be reported as positive for organism detection, with treating clinicians alerted 
to the option for reflex toxin EIA (high specificity for active infection) testing if 
warranted by the clinical scenario (1, 12). The main benefit of this algorithmic approach 
is that treating clinicians receive the benefit of knowing if the organism is present 
utilizing the most sensitive testing strategy (NAAT; MFI of 150) and receive either an 
immediate estimate of organism burden indicating that the patient is likely actively 
infected (MFI of 1,200) or the option for reflex testing to detect the etiologic agent of 
disease (toxin protein; MFI of 150 but 1,200). Clinicians can then correlate these 
data with the clinical scenario to make more informed decisions affecting patient care. 
Establishing quantitative cutoffs to interpret molecular data is pointless if the 
numerical values corresponding to the outcome of interest fluctuate over time. In this 
study, we show that the MFI cutoff of 1,200 maintained its ability to accurately predict 
2-SA and toxin EIA positivity in a second cotested data set (n  1,432) with samples 
analyzed 1 year apart using multiple reagent lots, equipment updates, and variations in 
testing personnel. The robustness of MFI thresholds in the current study is similar to the 
high precision observed for Xpert PCR CT values (24) although additional studies at 
multiple testing sites are required for a more thorough evaluation.
Analysis of data set 1 reveals that out of 1,670 samples tested with the GPP assay 
over a 1-year period, 1,440 (86%) would have been reported out as negative utilizing 
the proposed algorithm. Had the option to report C. difficile results from the GPP been 
available at the time, no doubt a significant subset of the 1,105 (66%) cotested samples 
would have been analyzed by the syndromic panel alone without the need for 
additional testing. If GPP ordering had been combined with proper lab test utilization 
control methods (33), such as electronic hard stops and house staff education, the 
ability to report C. difficile from the GPP would have ultimately reduced costs associated 
with cotesting (13, 34).
Implementation of C. difficile reporting from syndromic panels as an adjunct to 
directed-testing strategies also has the potential to raise health care costs. If given the 
option of obtaining C. difficile results from either assay, many clinicians, especially those 
with low to intermediate concern for C. difficile infection, would likely choose the more 
expensive syndromic panel to simultaneously detect other potential pathogens. Lab-
oratories that choose to report C. difficile results from both assays should be aware of 
the potential for abuse and take the appropriate steps to mitigate inappropriate lab test 
utilization. Provider education about the cost of laboratory tests and electronic hard 
stops during the test ordering process should emphasize (i) that directed-testing 
strategies are the more accurate and cost-effective method to detect C. difficile, (ii) that 
testing should not be performed on patients exposed to laxatives due to high false-
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Antimicrob Chemother 62:388–396. https://doi.org/10.1093/jac/dkn163.
16. Chitnis AS, Holzbauer SM, Belflower RM, Winston LG, Bamberg WM,
Lyons C, Farley MM, Dumyati GK, Wilson LE, Beldavs ZG, Dunn JR,
Gould LH, MacCannell DR, Gerding DN, McDonald LC, Lessa FC. 2013.
Epidemiology of community-associated Clostridium difficile infec-
positive rates, and (iii) that director approval should be required for inpatients hospi-
talized for 72 h (33).
It is important that in addition to the 21 positive cases of C. difficile, 86 other 
pathogens were identified and reported out from the 563 samples analyzed by the GPP 
alone. These pathogens are listed in order of increasing frequency: norovirus, Campy-
lobacter, Salmonella, Escherichia coli STEC/O157, Giardia, Shigella, rotavirus, and Cryp-
tosporidium. The overlapping clinical syndromes associated with these organisms 
makes multiplex PCR a powerful technology in the diagnosis of GI infections, and its 
utilization in clinical laboratories continues to increase despite high costs and reim-
bursement challenges (13). Similar to published reports, we also observed a significant 
number of samples with codetection of C. difficile and a second pathogen (25, 26, 35). 
It is not clear if codetection represents true coinfection or detection of asymptomatic 
carriage in a patient with diarrheal illness due to the other pathogen (4). However, chart 
reviews performed on six samples with codetection of C. difficile and a second patho-
gen (four norovirus, one Campylobacter, and one adenovirus by PCR) identified all as 
false positives, suggesting bystander detection and not active infection.
In summary, although directed-testing strategies are the preferred diagnostic ap-
proach, their value is contingent upon clinical suspicion for C. difficile infection. Med-
icine is as much an art as it is a science, and as recently shown, up to 60% of community 
onset cases will not elicit an order for C. difficile testing (18). The attraction of this 
algorithmic approach to reporting C. difficile results from multiplex PCR assays is that it 
serves as an adjunct to supplement, not replace, directed-testing strategies while 
simultaneously capturing atypical infections, irrespective of initial clinical suspicion, and 
a plethora of GI pathogens that cause the same nondescript diarrheal syndrome.
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